Cite
HARVARD Citation
Hampton, P. et al. (2021). Twelve‐week secukinumab treatment is consistently efficacious for moderate‐to‐severe psoriasis regardless of prior biologic and non‐biologic systemic treatment: Post hoc analysis of six randomised trials. Journal of the European Academy of Dermatology and Venereology. pp. 928-937. [Online].